Structure-guided discovery of a single-domain antibody agonist against human apelin receptor.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 31998837.
- Also identified by DOI 10.1126/sciadv.aax7379 and PMC identifier 6962038.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Developing antibody agonists targeting the human apelin receptor (APJ) is a promising therapeutic approach for the treatment of chronic heart failure. Here, we report the structure-guided discovery of a single-domain antibody (sdAb) agonist JN241-9, based on the cocrystal structure of APJ with an sdAb antagonist JN241, the first cocrystal structure of a class A G protein-coupled receptor (GPCR) with a functional antibody. As revealed by the structure, JN241 binds to the extracellular side of APJ, makes critical contacts with the second extracellular loop, and inserts the CDR3 into the ligand-binding pocket. We converted JN241 into a full agonist JN241-9 by inserting a tyrosine into the CDR3. Modeling and molecular dynamics simulation shed light on JN241-9-stimulated receptor activation, providing structural insights for finding agonistic antibodies against class A GPCRs.
Medical subject headings
- Apelin Receptors
- Drug Discovery
- Quantitative Structure-Activity Relationship
- Single-Domain Antibodies